An in-depth look to MEDIGEN BIOTECHNOLOGY CORPORATION operating, investing, and financing activities

3176 free cash flow for Q1 24 is -19.6 M TWD. For 2023, 3176 free cash flow was -607.81 M TWD and operating cash flow was -569.4 M TWD.